Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Trial Profile

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2019

At a glance

  • Drugs Perillyl alcohol (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NEONC Technologies
  • Most Recent Events

    • 03 Apr 2019 This is the first FDA approved trial for intranasal delivery to malignant gliomas, and to date 8 patients have been enrolled as per trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 27 Aug 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top